SomaLogic launches SOMAmer Discovery Service, “SOMAmer Challenge”

SomaLogic launches SOMAmer Discovery Service, “SOMAmer Challenge”

10/30/2014

SomaLogic announced today the launch of a new proteomics service offering aimed at providing its breakthrough protein-binding SOMAmer® reagents to the scientific community based on their specific needs in wide variety of different research uses. The SOMAmer Discovery Service team at SomaLogic will work closely with SomaLogic customers to develop and license “fit-for-purpose” SOMAmer reagents that strongly bind the customers’ proteins of interest, and function correctly in the particular assays they are performing with the reagents.

To celebrate the launch of this new service, SomaLogic is sponsoring the “SOMAmer Challenge,” a contest in which participants can name specific proteins of interest for a chance to win a free SOMAmer Discovery Service package.

SOMAmer (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic’s proteomics technology platform, are a new class of superior protein-binding reagents that combine the high specificity and affinity of monoclonal antibodies with the stability and lot-to-lot consistency of traditional aptamers. They have wide applicability in many current preclinical and clinical analytical assays, including quantitative high-content screening, targeted panels, flow cytometry, histochemistry, functional assays, and biophysical methods.

“We are delighted that we can now offer our SOMAmer Discovery Service to scientists looking for specific, dependable protein-binding molecules for their particular research needs,” said Paul Menter, Vice President and General Manager of Life Science at SomaLogic. “We believe that this service fills a critical need for high affinity and robust binding reagents for many different laboratory applications.”

Compared to other available proteomic technologies, SomaLogic’s offerings provide researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SomaLogic’s commercially available SOMAscan™ assay, which incorporates 1129 different SOMAmer reagents in the current version, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

Looking for the Newest Annotated List of SOMAscan Assay Publications?

Subscribe to be notified when a new annotated list is available


SomaLogic announces Novartis agreement extension, equity investment

SomaLogic announces Novartis agreement extension, equity investment

10/20/2014

SomaLogic, Inc. announced today that Novartis has extended its multi-year research agreement for the development and application of SomaLogic’s unique proteomics technology to Novartis’ drug discovery and development efforts. Novartis will also take an equity position in SomaLogic under the agreement extension.

Under the previous collaboration agreement, scientists at the Novartis Institutes for BioMedical Research (NIBR) and SomaLogic worked together to build an enhanced proprietary version of SomaLogic’s SOMAscan™ proteomics assay for NIBR. The collaboration also included development of specific novel SOMAmer® (Slow Off-rate Modified Aptamer) binding reagents for multiple preclinical and clinical applications in NIBR’s research and development portfolio. The collaboration extension announced today will enhance and expand these efforts in addition to the equity investment in SomaLogic. Other specific terms of the agreement were not disclosed.

“Our ongoing relationship with Novartis is a model for how we seek to develop strong scientific collaborations that drive new discoveries and build value for both parties,” said Byron Hewett, Chief Executive Officer of SomaLogic. “We are delighted that Novartis has decided to continue our work together, and take it to an even higher level.”

Compared to other current proteomic technologies, SomaLogic’s offerings provide researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. They have wide applicability in many current preclinical and clinical analytical assays, including quantitative high-content screening, targeted panels, flow cytometry, histochemistry, functional assays, and biophysical methods. SomaLogic’s commercially available SOMAscan assay, which incorporates 1129 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

Looking for the Newest Annotated List of SOMAscan Assay Publications?

Subscribe to be notified when a new annotated list is available


SomaLogic announces agreement to deploy SOMAscan assay at NIH Center

SomaLogic announces agreement to deploy SOMAscan assay at NIH Center

10/13/2014

SomaLogic, Inc. announced today that the National Institutes of Health (NIH) Center for Human Immunology, Autoimmunity and Inflammation (CHI) will use the SOMAscan™ proteomics assay for research with collaborators across the NIH. It is expected that the SOMAscan assay will be installed and fully functional at CHI by the beginning of 2015, under the leadership of CHI Director Neal S. Young, M.D.

“CHI’s mission is to perform cooperative research based on advanced technologies in order to efficiently translate enhanced understanding of immune function and pathophysiology to the clinic,” said Dr. Young. “We believe the SOMAscan assay gives us a powerful new tool to open up proteomics research and biomarker discovery to many more NIH scientists who are performing a wide variety of critical preclinical and clinical studies.”

Compared to other current proteomic technologies, SomaLogic’s offerings provide researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer® (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1129 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

“We are delighted to partner with NIH to give its world-class researchers access to the SOMAscan assay,” said Byron Hewett, Chief Executive Officer of SomaLogic. “CHI’s commitment to applying our technology to critical biomedical questions will help ensure the accelerated discovery of new biomarkers – and potentially new therapeutic approaches – for many different diseases.”

SomaLogic is continuing to expand access to its SOMAscan assay through its placement in leading academic research centers. Current sites, in addition to CHI, include Massachusetts General Hospital and the University of Pennsylvania, with several more expected to be announced in the coming weeks.

The trans-NIH CHI is sponsored by the National Cancer Institute, the

National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, the National Institute of Arthritis, Musculoskeletal and Skin Diseases, the National Institute of Child Health and Human Development, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Disorders and Stroke, the National Institute of Environmental Health Sciences, the National Eye Institute, the National Human Genome Research Institute, and the Food and Drug Administration. For more information about CHI, please visit

http://www.nhlbi.nih.gov/resources/chi/


Children’s Hospital Colorado and SomaLogic Announce Collaboration to Develop Novel Diagnostic Tests

Children’s Hospital Colorado and SomaLogic Announce Collaboration to Develop Novel Diagnostic Tests

10/8/2014

Children’s Hospital Colorado and SomaLogic, Inc. announced today that they have entered into a collaborative agreement to discover protein biomarkers and use those biomarkers to develop laboratory tests to improve the diagnosis and management of childhood diseases. The discovery and development work will be done using SomaLogic’s novel proteomics SOMAscan™ assay, which can measure more than a thousand proteins in a small amount of blood or other biological samples. This innovative collaboration is being entered into as a result of successful initial exploratory research done by the two organizations.

The research team will be led by Robin Deterding, M.D., Director of the Breathing Institute at Children’s Colorado, Professor of Pulmonary Medicine in the Department of Pediatrics at the University of Colorado School of Medicine, and Chair of the North American Children’s Interstitial and Diffuse Lung Disease Research Network (CHILDRN). Deterding is an international expert in the care of children with rare diffuse lung disease.

“We have a unique ‘game changing’ opportunity to rapidly discover and apply blood-based protein biomarkers for the early diagnosis of rare and common pediatric lung diseases, but also for the diagnosis, prognosis and monitoring of many other childhood diseases. ” said Dr. Deterding. “My colleagues and I are excited to continue our initial exploratory work with SomaLogic and their unprecedented protein measuring technology to find breakthrough new tools to dramatically improve the clinical care of children.”

Under the agreement, researchers at Children’s Colorado and SomaLogic will work together to widely analyze the proteins from blood samples obtained from children suffering from disease. They will then select those proteins, or biomarkers, whose change in concentration is correlated with disease (and its severity) to serve as a basis for developing in-house diagnostic tests for future clinical use. These tests will rely on SomaLogic’s technology, which can be scaled to measure from thousands of proteins for discovery of biomarkers to only a few selected proteins for diagnostic purposes.

“This collaboration with Children’s Hospital and CU School of Medicine faculty is the ideal model for how we would like to see our technology used by academic research centers to make a difference in the lives of patients,” said Byron Hewett, Chief Executive Officer of SomaLogic. “Their clinical insight and expertise matched to our proteomics expertise should lead to both a deeper understanding of the biology of these devastating diseases, and to new ways to manage them more precisely and effectively.”

“We are excited about the possibilities this partnership will develop for earlier identification and improved management of childhood diseases. SomaLogic’s innovative technology coupled with our clinical expertise will allow us to diagnose and ultimately improve treatment for children everywhere”, said Jim Shmerling, CEO of Children’s Hospital Colorado.

Financial details of the collaborative agreement were not disclosed.


NEC Corporation to market SomaLogic’s SOMAscan™ assay in Japan

NEC Corporation to market SomaLogic’s SOMAscan™ assay in Japan

9/29/2014

SomaLogic, Inc. and NEC Corporation (TYO: 6701) announced today an agreement that gives NEC exclusive marketing rights in Japan for SomaLogic’s SOMAscan™ assay, which is built on SomaLogic’s proprietary SOMAmer® technology. Under the agreement, NEC will offer access to the SOMAscan assay to biopharmaceutical companies, food companies, and academic research centers for their research in Japan.

SomaLogic’s breakthrough SOMAscan proteomic assay efficiently, accurately, and rapidly identifies and quantifies 1,129 proteins across a wide range of concentrations in small volumes of multiple biological sample types. Compared to other current proteomic technologies, SomaLogic’s breadth and depth of coverage offers unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development.

This new collaboration expands on a 2010 agreement between NEC and SomaLogic to explore applications of SomaLogic’s technology in the life sciences and healthcare markets. Under the previous agreement, NEC developed the SomaSuite™ software tool, which facilitates the interpretation of the large data sets produced by the SOMAscan assay. The SomaSuite software will also be provided to Japanese SOMAscan assay clients under the new agreement.

Both of these agreements with SomaLogic reflect NEC’s growing emphasis on applying its deep computational expertise to become a world leader in providing novel healthcare solutions. For more information about NEC Corporation, visit its website at http://www.nec.com.


Massachusetts General Hospital is newest SOMAscan™ assay site

Massachusetts General Hospital is newest SOMAscan™ assay site

8/19/2014

SomaLogic, Inc. announced today that Massachusetts General Hospital (MGH) will be the first Boston-area biomedical research center to perform on-site studies using the SOMAscan™ assay, a breakthrough proteomics platform that can measure more than a thousand proteins in a small amount of blood or other biological sample. The SOMAscan assay will be performed under the direction of Robert Gerszten, MD, Director of Clinical and Translational Research of the MGH Heart Center and Professor of Medicine at Harvard Medical School. It is expected that the SOMAscan assay will be installed and fully functional at MGH by mid-fall of 2014.

“We are delighted to partner with such a world-class institute as Massachusetts General Hospital to bring our powerful technology to more researchers,” said Byron Hewett, Chief Executive Officer of SomaLogic. “The leadership of Dr. Gerszten, together with MGH’s deep expertise in applying cutting edge biotechnology tools to critical biomedical questions, will help ensure that the SOMAscan assay will contribute to new biomarker discoveries, and potentially to new therapeutic approaches for treating diseases.”

Compared to other current proteomic technologies, the SOMAscan proteomic assay’s breadth and depth of coverage of the proteome offers significant new potential for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development.

“We have used the SOMAscan assay in previous work in mice and humans, and I believe that a technology like this has the potential to accelerate translational research across many different diseases and conditions. We expect to be able to offer this assay to our colleagues, as they realize the potential of this platform for their own translational research efforts,” said Dr. Gerszten.

SomaLogic is continuing to expand access to its SOMAscan platform through its placement in leading academic research centers, and anticipates announcing several additional SOMAscan assay sites by the end of 2014.